pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Rezdiffra
drug
save

resmetirom

Marketedupdated 6mo ago
by $MDGL MADRIGAL PHARMACEUTICALS, INC.
Approved
community read0 votes

🐶 often sniffed alongside

top 3
  • tagApproval16 co-mentions · 4 sources
  • drugREZDIFFRA16 co-mentions · 4 sources
  • tagSmall Molecule8 co-mentions · 4 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for non-alcoholic fatty liver disease and cirrhosis of liver and 5 investigational indications.

all catalysts(4)

approval · 4
Mar 14, 2024
approval
$MDGL431.00-2.12%
3y ago
REZDIFFRA (RESMETIROM) — FDA approval
resmetirom
→
Dec 19, 2025
approval
$MDGL431.00-2.12%
11mo ago
REZDIFFRA (RESMETIROM) — FDA approval
resmetirom
→
Dec 19, 2025
approval
$MDGL431.00-2.12%
11mo ago
REZDIFFRA (RESMETIROM) — FDA approval
resmetirom
→
Dec 19, 2025
approval
$MDGL431.00-2.12%
11mo ago
REZDIFFRA (RESMETIROM) — FDA approval
resmetirom
→

Trials studying resmetirom

  • phase4Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 Fibrosisrecruitingn=150
  • phase1Resmetirom in Patients With MASH and HFpEFrecruitingn=90
  • phase2Study of Resmetirom in Children and Adolescents With MASHrecruitingn=61
  • phase3A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)active not recruitingn=845
  • phase2Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASHrecruitingn=120
  • —Rezdiffra Pregnancy and Lactation Registryrecruitingn=10
  • phase1A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult Participantscompletedn=40
  • phase2Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)completedn=116

Patent cliff

source: FDA Orange Book
first barrier falls
Mar 14, 2029
~2.3 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (18)

  • Feb 4, 2045method-of-use (U-3861)US 12377104
  • Feb 4, 2045method-of-use (U-3861)US 12377104
  • Feb 4, 2045method-of-use (U-3861)US 12377104
  • Sep 17, 2033method-of-use (U-3861)US 10376517
  • Sep 17, 2033method-of-use (U-3861)US 10376517
  • Sep 17, 2033method-of-use (U-3861)US 10376517
  • Sep 17, 2033compositionUS 11564926
  • Sep 17, 2033compositionUS 11564926
  • Sep 17, 2033compositionUS 11564926
  • Sep 17, 2033method-of-use (U-3861)US 11986481
  • Sep 17, 2033method-of-use (U-3861)US 11986481
  • Sep 17, 2033method-of-use (U-3861)US 11986481
  • Sep 17, 2033compositionUS 9266861
  • Sep 17, 2033compositionUS 9266861
  • Sep 17, 2033compositionUS 9266861
  • Sep 12, 2026compositionUS 7452882
  • Sep 12, 2026compositionUS 7452882
  • Sep 12, 2026compositionUS 7452882

FDA exclusivities (3)

  • Mar 14, 2029NCENew Chemical Entity (5y)2.3y
  • Mar 14, 2029NCENew Chemical Entity (5y)2.3y
  • Mar 14, 2029NCENew Chemical Entity (5y)2.3y

News(10)

  • Altimmune gears up for FDA meeting on pivotal Phase 3 trial in alcohol use disorder
    Having linked its glucagon/GLP-1 candidate to a significant reduction in heavy drinking days, Altimmune is preparing to speak to the FDA in December about the design of a Phase 3 program.
    biospace · 6d ago
  • This week in charts: 3 drug launches Wall Street is watching
    The latest installment in BioPharma Dive’s visualization-focused series features a look at investors’ response to a trio of medicines highlighted in quarterly earnings this week.
    biopharma_dive · 11d ago
  • A treatment revolution is underway in MASH
    To build on the momentum in MASH, we—at Madrigal Pharmaceuticals and the industry more widely—must further expand approaches to diagnosis, monitoring and individualized treatment to help more patie…
    biospace · 12d ago
  • Madrigal’s former clinical development head files whistleblower lawsuit alleging Rezdiffra safety cover-up
    Madrigal Pharmaceuticals is facing a whistleblower lawsuit alleging that senior leadership censored serious liver-injury data related to its breakthrough MASH drug Rezdiffra and retaliated against…
    fiercebiotech · 13d ago
  • AstraZeneca bulks up MASH, cardio work in up to $1.5B AI partnership with insitro
    AstraZeneca will tap AI-focused insitro to find new targets for metabolic dysfunction-associated steatohepatitis and cardiomyopathies, following the Phase 3 failure of its Ionis-partnered Wainua in…
    biospace · 1mo ago
  • Siemens Healthineers and Novo team up on fatty liver disease awareness, testing
    Siemens Healthineers is joining forces with Novo to help boost awareness and diagnosis of fatty liver disease.
    fiercebiotech · 1mo ago
  • ‘It’s making a difference’: Madrigal CEO talks strategy behind MASH shopping spree
    Not content with navigating Rezdiffra’s trajectory to blockbuster territory, Madrigal Pharmaceuticals has spent 2026 shopping for a range of drugs that the company hopes could work alongside its me…
    fiercebiotech · 3mo ago
  • Rezdiffra is exceeding Wall Street's expectations as the MASH market takes shape
    It seems there’s room for two in the MASH market. When Novo Nordisk’s blockbuster weight loss drug Wegovy won approval in August 2025 to treat the fatty liver disease, some investors thought it wou…
    endpoints · 6mo ago
  • Madrigal's Rezdiffra beats estimates; Gilead cuts jobs; Banyan debuts
    🚀 Madrigal Pharmaceuticals' MASH drug beats expectations: The biotech’s Rezdiffra sales came in at $311 million for the first quarter, surpassing analysts’ projections by about $10 million, accord…
    endpoints · 6mo ago
  • STAT+: Novo Nordisk’s less-bad news on its Wegovy pill boosts earnings and share price
    Vivek Ramaswamy wins GOP primary for Ohio governor, CellCentric raises $220M for myeloma drug, and more biotech news
    stat · 6mo ago
view all news mentions →
brand
Rezdiffra
generic
resmetirom
MOA
Thyroid hormone receptor beta-1 agonist
indication
Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH)
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 5h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?